1. Home
  2. BCRX vs EVO Comparison

BCRX vs EVO Comparison

Compare BCRX & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCRX
  • EVO
  • Stock Information
  • Founded
  • BCRX 1986
  • EVO 1993
  • Country
  • BCRX United States
  • EVO Germany
  • Employees
  • BCRX N/A
  • EVO N/A
  • Industry
  • BCRX Biotechnology: Biological Products (No Diagnostic Substances)
  • EVO Biotechnology: Pharmaceutical Preparations
  • Sector
  • BCRX Health Care
  • EVO Health Care
  • Exchange
  • BCRX Nasdaq
  • EVO Nasdaq
  • Market Cap
  • BCRX 1.9B
  • EVO 1.6B
  • IPO Year
  • BCRX 1994
  • EVO 2021
  • Fundamental
  • Price
  • BCRX $9.21
  • EVO $4.44
  • Analyst Decision
  • BCRX Buy
  • EVO Buy
  • Analyst Count
  • BCRX 6
  • EVO 2
  • Target Price
  • BCRX $15.50
  • EVO $5.90
  • AVG Volume (30 Days)
  • BCRX 3.0M
  • EVO 46.1K
  • Earning Date
  • BCRX 02-24-2025
  • EVO 11-06-2024
  • Dividend Yield
  • BCRX N/A
  • EVO N/A
  • EPS Growth
  • BCRX N/A
  • EVO N/A
  • EPS
  • BCRX N/A
  • EVO N/A
  • Revenue
  • BCRX $412,579,000.00
  • EVO $866,665,179.00
  • Revenue This Year
  • BCRX $38.44
  • EVO $3.84
  • Revenue Next Year
  • BCRX $21.23
  • EVO $10.94
  • P/E Ratio
  • BCRX N/A
  • EVO N/A
  • Revenue Growth
  • BCRX 29.92
  • EVO N/A
  • 52 Week Low
  • BCRX $4.03
  • EVO $2.85
  • 52 Week High
  • BCRX $9.50
  • EVO $7.98
  • Technical
  • Relative Strength Index (RSI)
  • BCRX 65.48
  • EVO 49.82
  • Support Level
  • BCRX $8.63
  • EVO $4.40
  • Resistance Level
  • BCRX $9.00
  • EVO $4.49
  • Average True Range (ATR)
  • BCRX 0.36
  • EVO 0.10
  • MACD
  • BCRX 0.07
  • EVO -0.00
  • Stochastic Oscillator
  • BCRX 85.20
  • EVO 38.46

About BCRX BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: